You are managing a pharmaceutical product launch project using a hybrid approach. Clinical trials and regulatory submissions follow a stage-gate predictive model due to FDA requirements, while the marketing campaign and digital presence are developed using Scrum. The regulatory team has just learned that the FDA will require an additional study, delaying approval by 9 months. Meanwhile, the Scrum team has completed the e-commerce platform, mobile app, and digital marketing materials scheduled for the original launch date. The program sponsor is concerned about losing competitive advantage and wants options for generating value from the completed digital work. What is the MOST appropriate strategy?

Question

Accepted Answer

The correct answer is A. Option A is correct because it exemplifies adaptive value optimization within regulatory constraints (ECO Process Task 2.1 - Execute project with urgency required to deliver business value). In hybrid projects, when one stream is constrained, effective PMs find ways to generate value from unconstrained streams while respecting necessary boundaries. Building community, education, and brand awareness can create legitimate value and prepare the market without making product claims that violate FDA regulations. Option B, the main distractor, seems action-oriented but creates significant legal and regulatory risks - pharmaceutical marketing is heavily regulated, and premature product promotion could jeopardize FDA approval entirely. Option C wastes organizational capability and loses team momentum and knowledge. Option D, while potentially valuable, doesn't address the sponsor's specific concern about immediate competitive advantage and value realization from already-completed work. In hybrid environments, PMs must balance compliance requirements with agile value delivery principles.

PMP Practice Question: Process — Hybrid, Hard

More Process Questions